Lifeboat Foundation

Companies that embrace a data-driven culture will be better able to thrive in not just life sciences, but every industry. By leveraging AI and strengthening the collaboration between humans and machines, organizations can achieve better quality, ensure data-driven decision-making and democratize data across their enterprise.

It’s incredible to think of where we’ll be in just a few short years. Those who can adapt to a data-first culture and not only implement AI technologies, but also understand its application and address the challenges, will be better positioned for success.

I’ll close with this—follow the data. Make decisions based on that data. That’s it. It’s that simple. In the search for truth, data-driven decisions are the way forward.

Improvements in public health and medicine have lengthened human survival, but science has yet to overcome ageing.

Edward Frenkel is a renowned mathematician, professor of University of California, Berkeley, member of the American Academy of Arts and Sciences, and winner of the Hermann Weyl Prize in Mathematical Physics. In this episode, Edward Frenkel discusses the recent monumental proof in the Langlands program, explaining its significance and how it advances understanding in modern mathematics.

SPONSOR (THE ECONOMIST): As a listener of TOE you can get a special 20% off discount to The Economist and all it has to offer! Visit https://www.economist.com/toe.

Continue reading “This is a Monumental Breakthrough… [Part 2]” »

Well it does kinda look like a stapler.

This wild-looking people mover can transport up to 20, Musk said.

They say aging is just a part of life, but have you ever wondered if it really has to be? What if getting older isn’t just something we accept but something we could actually treat?

In this riveting episode of Peak Human Labs Podcast, Dr. Sanjeev Goel, sits down with Dr. Aubrey de Grey, a trailblazing biomedical gerontologist and Chief Science Officer of the SENS Research Foundation. They dive deep into the revolutionary idea of treating aging as a medical condition. They explore how damage accumulates in our bodies over time and discuss the groundbreaking medical advancements that could extend our healthy lifespans. Dr. de Grey sheds light on the crucial need for investing in underfunded research and shares insights into the future of longevity science. Tune in and envision a future where health and longevity are not just aspirations but achievable realities!

Continue reading “How far till Longevity Escape Velocity?” »

Pigs are considered useful biomedical models for humans so the implications of such studies sent waves through the field of resuscitation — and bioethics.

At the recent annual International AIDS Conference, a startling presentation about the newest wonder drug in HIV prevention brought a raucous standing ovation.

But some of us in the public health community are now starting to wonder what all the cheering was about. Although the scientific results were impeccable, the process for translating those results into action for young women in Africa has been left to our imaginations. And if history is any guide, this could be a nightmare.

When the results first came out, Gilead, the manufacturer of lenacapavir, stated it was too early to discuss licensing and offering vague plans about its production and availability in Africa. Just recently, a second study among men who have sex with men and predominantly conducted in the Northern Hemisphere showed similarly promising results. While Gilead now says they have sufficient data to move ahead with licensing and manufacturing worldwide, they have offered no timeline to do so. Urgency to report trial results has not been mirrored by the urgency to provide access. Unanswered questions remain about why another study was needed to move ahead with approvals for use in African women, and if and when lenacapavir will be made available at an affordable price in the African region.

Continue reading “Tested in Africa, used in America” »